Nordic Nanovector (OB:NANOV) - Share price, News & Analysis

NANOV fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

NANOV Stock Overview

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway.

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (NOK0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

+ 1 more risk

Nordic Nanovector Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nordic Nanovector
Historical stock prices
Current Share Price	kr10.72
52 Week High	kr33.80
52 Week Low	kr10.58
Beta	1.55
1 Month Change	-23.54%
3 Month Change	-18.04%
1 Year Change	-57.53%
3 Year Change	-74.02%
5 Year Change	-88.89%
Change since IPO	-61.71%

Shareholder Returns

	NANOV	NO Biotechs	NO Market
7D	-20.6%	-6.1%	-1.2%
1Y	-57.5%	-48.9%	12.6%

Return vs Industry: NANOV underperformed the Norwegian Biotechs industry which returned -48.9% over the past year.

Return vs Market: NANOV underperformed the Norwegian Market which returned 12.6% over the past year.

Price Volatility

Is NANOV's price volatile compared to industry and market?
NANOV volatility
NANOV Average Weekly Movement	10.0%
Biotechs Industry Average Movement	8.9%
Market Average Movement	7.4%
10% most volatile stocks in NO Market	12.4%
10% least volatile stocks in NO Market	4.2%

Stable Share Price: NANOV is more volatile than 75% of Norwegian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: NANOV's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.

About the Company

Founded	Employees	CEO	Website
2009	38	Erik Skullerud	https://www.nordicnanovector.com

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company’s lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia.

Nordic Nanovector Fundamentals Summary

How do Nordic Nanovector's earnings and revenue compare to its market cap?
NANOV fundamental statistics
Market Cap	kr1.28b
Earnings (TTM)	-kr444.55m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.8x

P/E Ratio

Is NANOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NANOV income statement (TTM)
Revenue	kr0
Cost of Revenue	kr0
Gross Profit	kr0
Other Expenses	kr444.55m
Earnings	-kr444.55m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jul 20, 2022

Earnings per share (EPS)	-3.83
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did NANOV perform over the long term?

See historical performance and comparison

Valuation

Is Nordic Nanovector undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.59x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NANOV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NANOV's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: NANOV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: NANOV is unprofitable, so we can't compare its PE Ratio to the Norwegian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NANOV's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: NANOV is overvalued based on its PB Ratio (4.6x) compared to the NO Biotechs industry average (3.9x).

Future Growth

How is Nordic Nanovector forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

11.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NANOV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NANOV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NANOV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NANOV is forecast to have no revenue next year.

High Growth Revenue: NANOV is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NANOV's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Nordic Nanovector performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-11.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NANOV is currently unprofitable.

Growing Profit Margin: NANOV is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NANOV is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.

Accelerating Growth: Unable to compare NANOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NANOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-5.2%).

Return on Equity

High ROE: NANOV has a negative Return on Equity (-163.87%), as it is currently unprofitable.

Financial Health

How is Nordic Nanovector's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NANOV's short term assets (NOK376.4M) exceed its short term liabilities (NOK103.8M).

Long Term Liabilities: NANOV's short term assets (NOK376.4M) exceed its long term liabilities (NOK4.4M).

Debt to Equity History and Analysis

Debt Level: NANOV is debt free.

Reducing Debt: NANOV has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NANOV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NANOV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.9% each year

Dividend

What is Nordic Nanovector current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NANOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NANOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NANOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NANOV's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NANOV has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure

CEO

Erik Skullerud (52 yo)

0.67

Tenure

kr5,845,620

Compensation

Mr. Erik Skullerud is Chief Executive Officer of Nordic Nanovector ASA from September 20, 2021. Mr. Skullerud joins the Company from Element Consulting GmbH, a globally focused boutique advisory and consul...

CEO Compensation Analysis

Compensation vs Market: Erik's total compensation ($USD597.83K) is above average for companies of similar size in the Norwegian market ($USD330.08K).

Compensation vs Earnings: Insufficient data to compare Erik's compensation with company performance.

Leadership Team

Experienced Management: NANOV's management team is considered experienced (2.4 years average tenure).

Board Members

Experienced Board: NANOV's board of directors are considered experienced (7 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/16 00:00
End of Day Share Price	2022/05/16 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31